Authors

  • Mullokulov J., Akhmedov Kh., Anorboev M.

Keywords:

Reactive arthritis; Golimumab; Tofacitinib; TNF-α inhibitor; JAK inhibitor; Cytokines; Real-world study; Uzbekistan.

References

Cohen S, Curtis JR, et al. JAK inhibitors in inflammatory arthritis: balancing efficacy and safety. Nat Rev Rheumatol. 2023;19(4):223–237.

Gudu T, Gossec L. Quality of life and work productivity in spondyloarthritis. RMD Open. 2018;4(Suppl 1):e000762.

Kwon OC, Lee JS, et al. Efficacy of JAK inhibitors in refractory reactive arthritis: a multicenter case series. Clin Rheumatol. 2022;41(9):2735–2742.

Mease PJ, Rahman P, Gottlieb AB, et al. Long-term safety of tofacitinib in psoriatic arthritis up to 48 months. Rheumatology (Oxford). 2021;60(5):2401–2412.

Mease PJ, Smolen JS, Behrens F, et al. Efficacy of tofacitinib in psoriatic arthritis: 52-week results. N Engl J Med. 2017;377(16):1537–1550.

Poddubnyy D, Sieper J. Mechanistic and clinical insights into spondyloarthritis pathogenesis. Lancet Rheumatol. 2020;2(7):e382–e392.

Rahman MU, Inman RD, et al. Golimumab in spondyloarthritis: long-term real-world outcomes. Clin Rheumatol. 2020;39(12):3561–3571.

Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84.

Smolen JS, Landewé R, et al. EULAR recommendations for the management of spondyloarthritis. Ann Rheum Dis. 2023;82(4):515–529.

Song IH, van der Heijde D, et al. Efficacy and safety of tofacitinib versus adalimumab in psoriatic arthritis: 52-week results. Ann Rheum Dis. 2019;78(5):696–705.

van der Heijde D, Landewé R, et al. Long-term efficacy and safety of golimumab in ankylosing spondylitis: GO-RAISE study. Arthritis Rheumatol. 2020;72(6):910–919.

van der Heijde D, Song IH, et al. Tofacitinib or adalimumab versus placebo in psoriatic arthritis. N Engl J Med. 2017;377(16):1525–1536.

Verhoeven F, Wendling D. Novel therapeutic strategies in reactive arthritis. Autoimmun Rev. 2021;20(10):102933.

Wendling D, Prati C. Reactive arthritis: From clinical manifestations to treatment. Curr Rheumatol Rep. 2021;23(2):10.

Wendling D, Verhoeven F, Prati C. JAK inhibitors and reactive arthritis: a mechanistic update. Clin Exp Rheumatol. 2022;40(9):1681–1688.

Winthrop KL, et al. Infections and safety outcomes of JAK inhibitors: integrated analysis across rheumatic diseases. Arthritis Rheumatol. 2022;74(9):1520–1531.

Wu D, Guo H, et al. Cytokine and biomarker changes in reactive arthritis under JAK inhibition. Front Immunol. 2023; 14:1162821.

Xu H, Huang X, et al. Comparative cytokine suppression by TNF inhibitors and JAK inhibitors in spondyloarthritis. Clin Transl Immunol. 2021;10(3):e1281.

Zhang Y, Li W, et al. Regional perspectives in rheumatology: biologic and JAK inhibitor use in Central Asia. Clin Rheumatol. 2024;43(2):689–699.

Anorboyev Maruf Kholbuta ugli, et al. Rheumatoid arthritis: new treatment approaches - a comparative evidence review/ https://tbcenter.uz/ 8 (№13) 2025

Mullokulov Javohir et al. Comparative efficacy and safety of baricitinib plus sulfasalazine versus TNF-α inhibitors and sulfasalazine monotherapy in reactive arthritis: a 12-month randomized study/ https://tbcenter.uz/ 8 (№13) 2025

Mullokulov Javohir et al. Dynamics of serum anxa1 levels during treatment with baricitinib and sulfasalazine/ journals.tma.uz/ № 8, 2025. Vol. 1